A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

NCT05268666 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Solid Tumor
Metastatic Solid Tumor

Interventions

DRUG: JBI-802

Sponsor

Jubilant Therapeutics Inc.